Tag Archive for: Tivicay

The World Health Organization on Tuesday flagged growing HIV drug resistance against GSK and ViiV Healthcare’s antiretroviral medication Tivicay (dolutegravir), noting that observational and survey data suggest that resistance may now be higher than levels observed in clinical trials.

Targeted business development acquisitions, improvements in R&D and operating performance, and a strengthened post-demerger balance sheet are creating new capacity and flexibility for GSK to invest in growth and innovation for patients and shareholders.